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Summary 
To study the factors  that determine whether CD4 + T  cells produce interleukin 4  (II.-4) or 
interferon 3' (IFN-3')  upon stimulation we used a system allowing naive T  cells to be primed 
in vitro by  spedfic antigen.  Dense CD4 +  T  cells were purified from mice that  expressed 
transgenes encoding a T cell receptor specific  for pigeon cytochrome C peptide 88-104 in association 
with I-E  k. These T  cells produced very limited amounts of Ib4 and IFN-3' upon immediate 
challenge with 88-104 and antigen-presenting cells (APC). However, after an initial "priming" 
culture in which they were incubated for 4 d in the presence of 88-104, APC, and 1,000 U/m1 
IL-4, the T ceUs acquired the capacity to produce substantial amounts of IL-4 upon rechallenge 
but made very little IFN-3'. Cells primed in the absence of ID4 produced IFN-3' upon rechallenge 
but virtually no II.-4. The inhibitory effect of II.-4 on IFN-3' production did no appear  to be 
mediated by the induction of Ibl0 production since IL-10 addition to initial cultures did not 
suppress priming for IFN-3" production, nor did anti-IL-10 block the inhibitory effect of II.-4. 
IFN-3' itself did not increase priming for IFN-3' production, nor did anti-IFN-3`  reduce such 
priming. IFN-3` did, however, diminish priming for II.-4 production when limiting amounts 
of Ib4 (100 U/ml) were used in the initial culture. The dominant effect of Ib4 in determining 
the lymphokine-producing phenotype of primed cells was observed with dendritic cells (DC), 
activated B cells, and I-Ek-transfected fibroblasts as APC. However,  the different APC did vary 
in their potency, with DC being superior to activated B cells, which were superior to transfected 
fibroblasts. 
I 
mmune responses are often characterized by a polarization 
in the lymphokines that CD4 + T  cells produce in vivo 
or in response to in vitro challenge (1-4),  showing domi- 
nance of Ib4 or IFN-3` production, respectively. The choice 
of lymphokines produced in response to infectious agents can 
often determine whether that response will be protective or 
not. For example, T cells from mice that develop a progres- 
sive infection with Leishmania major mainly produce II.-4 upon 
antigenic challenge, while mice in whom lesions heal mount 
an immune response characterized by the production of IFN-3` 
(1, 2). Thus, understanding the factors that determine which 
lymphokines will be produced is of considerable importance. 
Recent work has demonstrated that the presence of I1,4 during 
stimulation of resting T cells with polyclonal activators can 
give rise to T cell populations capable of high IL-4 produc- 
tion on secondary challenge (5-7). Furthermore, treating mice 
with anti-Ib4 at the time of infection with L. major causes 
mice that normally develop a response dominated by I1.-4 to 
produce IFN-3` instead and to heal their leishmanial lesions 
(8, 9). These results strongly suggest that lymphokines them- 
selves may play a central role in regulating the spectrum of 
lymphokines produced in an immune response. 
To examine the priming of T  cells during activation by 
specific antigen rather than polydonal activators, we used small 
dense T cells from mice transgenic for TCK o~ and B chain 
genes that encode a TCR specific for peptide 88-104 of pi- 
geon cytochrome C  in the context of I-E  k class II MHC 
molecules. These T cells respond to stimulation with APC 
and peptide 88-104 by secreting IL-2 but little II.-4 or IFN-3`. 
We show here that IL.4 is essential for in vitro antigen priming 
for II.-4 production upon restimulation and that such II.-4 
treatment profoundly inhibits the development of antigen- 
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served  using  dendritic  cells  (DC), 1 activated  B  cells,  and 
I-Ek-transfected fibroblasts  as APC. 
Materials and Methods 
Animals.  TCR transgenic mice were produced by microinjec- 
tion of genomic TCR constructs into [B10.S x  C57BL/6J]F1  fer- 
tilized eggs using standard techniques (10). The rearranged ce and 
chain gene constructs were made from DNA derived from the 
5C.C7 T cell clone (11), and were cointegrated and expressed under 
the control of the endogenous 3' B chain enhancer (Fazekas de St. 
Groth et al.,  manuscript in preparation). The -I line used in all 
the experiments detailed below was established and maintained by 
backcrossing to B10.A mice originally derived from The Jackson 
Laboratory (Bar Harbor, ME). All the mice used in experiments 
were homozygous for H-2  a and heterozygous for the integration 
ofTCR oe and B chains. APC were prepared from virus-free B10.A 
female mice, 8-12 wk old, obtained from the Division of Cancer 
Treatment, National Cancer Institute (Frederick, MD). 
Tissue Culture Medium.  KPMI 1640 supplemented with 10% 
heat-inactivated FCS,  penicillin  (100  U/ml),  streptomycin (100 
#g/ml), I mM sodium pyruvate, t-glutamine (2 mM), and 2-ME 
(50/~M) was used for all stimulations and assays. 
Peptide.  A peptide with the sequence corresponding to residues 
88-104 of pigeon cytochrome C (KAERADLIAYLKQATAK) was 
synthesized by the National Institutes of Allergy and Infectious 
Diseases (NIAID) Biological  Resources Branch (Bethesda,  MD). 
RecombinantLymphokines.  Human I1:2 was a gift of  Cetus Corp. 
(Emeryville, CA).  I1:2  activity was  defined in terms of "Cetus 
Units." One Cetus unit is equivalent to '~0.3 ng. Mouse rIL-4 was 
was obtained by a baculovirus expression system, utilizing a vector 
into which the I1:4 gene had been inserted by C. Watson (Labora- 
tory of Immunology, NIAID). One unit of I1:4 is equivalent to 
"~0.5  pg.  Mouse  ri1:10 was  a  generous gift  of DNAX  (Palo 
Alto, CA). Mouse IFN-'r  was purchased from Genzyme (Cam- 
bridge,  MA). 
Preparation of.Accessory Cells.  Highly enriched DC were pre- 
pared from spleen ceUs of B10,A mice by allowing 2  x  10  s calls 
in 10 ml complete RPMI to adhere to plates  (3025;  Falcon Lab- 
ware, Oxnard, CA) for 2 h at 37~  Nonadherent cells were then 
discarded,  plates  washed three times with complete RPMI,  and 
10 ml of fresh medium was added.  After overnight incubation at 
37~  the DC became nonadherent and were collected, centrifuged 
over a 50% Percoll (Pharmacia Fine Chemicals, Piscataway, NJ) 
solution, and assessed for purity by flow cytometric analysis. They 
were found to be 75-85% enriched for DC as judged by staining 
with biotinylated mAb 33D1 and streptavidin-PE. Cells were briefly 
incubated with the anti-Fc3~RII/III  antibody 2.4G2 (12) before 
adding 33D1  to block binding of 33D1 to such Fc receptors. 
Activated B cells were prepared from spleens of B10.A mice as 
follows: single cell suspensions,  depleted of erythrocytes by ACK 
lysing buffer, were incubated with a mixture of anti-Thy-l.2 (HO- 
13.4) (13), anti-CD4 (GK1.5) (14), and anti-Lyt-2 0.155) (15) hy- 
bridoma supernatants for 15 min on ice, and then for 45 min at 
37~  in the presence of mouse rat anti-Ig antibody (MAR 18.5, 
ATCC TIB216) and rabbit complement (Cedarlane, Westbury, NY). 
Cells were further enriched by harvesting the 60/70% fraction from 
a discontinuous Percoll density gradient. B cells were activated for 
1 Abbreviation used in this paper: DC, dendritic cells. 
48  h  with  5  #g/ml  of affinity-purified  goat  anti-mouse  IgM 
(Southern Biotechnology, Birmingham, AL) and 100 U/m1 of mu- 
rine ri1:4..Activated B cells were also prepared by stimulating resting 
B cells for 48 h with LPS (20 #g/ml). The purity of B cells was 
assessed by flow cytometry analysis using FITC-conjugated anti- 
B220 (6B2) (16) antibody. Generally, these cells were >99% B220 
positive. 
Fibroblasts  transfected with I-E  k were a generous gift of Dr. 
Ronald Germain (NIAID). 
Preparation ofT Cells.  Lymph node CD4 § T cells from trans- 
genic mice were prepared as previously described (5). Briefly, lymph 
node cells were incubated with antibodies to CD8 (2.43) (15), B220 
(6B2),  and/or  I-A  k  (11-3.25)  (17),  and  cells  expressing  these 
markers were removed by magnetic bead depletion. The residual 
cells were centrifuged on a discontinuous Percoll density gradient. 
The 60/70% fraction was harvested and subsequently used for all 
primary cultures.  The purity and  transgene  expression  of the 
CD4 + T cells were verified by flow cytometric analysis using two- 
color immunofluorescence with PE-labeled  anti-CD4 and FITC 
anti-Vcdl  (RRS-1) obtained from Pharmingen.  In most experi- 
ments, >90%  of CD4 T  cells expressed  Vc~11. 
Primary and Secondary Stimulation of Transgenic T Cells.  Primary 
stimulation was carried out by adding 5-6  x  10  s small CD4 + T 
cells to individual wells of 24-well plates  in a total volume of 1 
ml with accessory cells, peptide, and lymphokine as described in 
Results.  After 36-48 h, cells were transferred to 5-ml dishes and 
supplemented with fresh medium for an additional 48 h to allow 
for further expansion. T cells were then washed three times and 
10  s cells restimulated with peptide and APC in a total volume of 
200/~1 in microtiter plates. 36 h later, supernatants were collected 
and assayed for lymphokine. 
Measurement of Lymphokine  Production,  IFN-3, was assayed by 
specific two-site ELISAs (18, 19), with reference standard curves 
using known amounts of rlFN-3,. Lymphokine-dependent cell lines 
(CT.4S), an Ib4-dependent line (20), and CTLL, an I1:2-dependent 
cell line (21), were used to measure I1:4 and I1:2 production, respec- 
tively, using serial dilutions of supematants and comparing responses 
to those elicited by known amounts of routine ri1:4 and human 
II:2 as standards. Anti-I1:4 antibody (11Bll) was added to the CTLL 
cells to block any effect of I1:4 on these cells. Lymphokine produc- 
tion is reported in terms of the total lymphokine-producing ca- 
pacity of cells derived from a given priming culture (U/culture); 
the  amount  of lymphokine produced by  105 cells  in  the  "sec- 
ondary" culture is multiplied by the number of  cells harvested from 
the priming culture divided by 10  s. 
Antibodies.  Purified monoclonal rat anti-mouse 11,4 (111311) (22) 
was prepared by Verax Corporation (Lebanon, NH). Rat anti-mouse 
IFN-',/(XMG 1.2) (23), PgP-1 (lm7) (24), and LECAM-1 (MEL14) 
(25) were purchased from Pharmingen. Monoclonal rat anti-mouse 
11:1 receptor (type 1) was purchased from Genzyme. 33D1  (26) 
was obtained from American Type Culture Collection (Rockville, 
MD). Purified rat anti-mouse I1:10 (SXC 1) was a generous gift 
of Dr. Maureen Howard (DNAX Institute of Molecular and Cel- 
lular Biology, Palo Alto, CA) (27). 
Results 
Characterization  and Responses  of Initial  Cell Populations. 
Lines of mice carrying c~ and B  TCR genomic constructs 
derived from the helper T ceLl  line 5C.C7 were derived by stan- 
dard methods (Fazekas de St. Groth, B., et al., manuscript 
in preparation).  More than 90%  of CD4 + lymph node T 
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as indicated by staining with mAbs to Vall and V/~3. Dense 
CD4 + T cells were purified. More than 90% of these cells 
were Mel  14 +  (LECAM-1),  CD44  l~  (Pgp-1),  indicating 
that the cell population was highly enriched in naive T cells 
(data not shown). 
Freshly isolated transgenic CD4 + T cells produced small 
amounts of I1:4 or IFN-3' (<50 U/ml/105 cells) upon im- 
mediate challenge with 1/~M of the relevant peptide pigeon 
cytochrome C  (88-104) and 5  x  103 DC, as illustrated in 
Fig. 1. Results were generally similar with a wide range of 
peptide concentrations and with the use of activated B cells 
as APC. These cells could be primed under conditions de- 
scribed below to produce much larger amounts of either lym- 
phokine (>4,000 U/ml/105 cells) upon rechallenge with the 
same concentration of peptide and the same number of DC. 
The data on cells primed in vitro are shown here only to 
illustrate the poor production of these lymphokines by naive 
cells. 
In other experiments, the frequency of freshly prepared 
transgenic T  cells that could be acutely stimulated to pro- 
duce Ib4 (28) was shown to be <1/2,000 (data not shown), 
reinforcing the conclusion that among unprimed T cells from 
transgenic donors, I1:4 is produced by very few cells. 
11_,4 Present during Priming Determines the Pattern of Lym- 
phokines Produced upon Subsequent Challenge.  CD4 + T cells 
(llY/ml) from transgenic donors were primed in vitro by 
culture with DC (2  x  104/ml), peptide (10 tzM), and Ib2 
(10 U/ml) for 4 d, with or without I1:4 (1,000 U/ml) or 
anti-Ib4 (10/~g/ml). Generally,  priming cultures were es- 
tablished with a total of 5  x  105 cells. If either peptide or 
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Figure 1.  Transgenic T cells produce little Ib4 and tFN-"/upon pri- 
mary challenge. CD4 + transgenic T cells were prepared from naive mice 
and stimulated with dendritic cells and peptide for 36 h. Culture superna- 
rants were harvested and tested for production of Ib4 and IFN-3, (primary 
response [1~  Naive CD4 + T cells were also cultured for 4 d with den- 
dritic cells, peptide, and either I1.-4 or anti-IL-4. Cells were washed, and 
restimulated with dendritic cells and peptide. 36 h later, supernatants were 
harvested and tested for I1.-4 and IFN-3' production (secondary response 
[2~  To prime for IL-4 production, IL-4 (1,000 U/ml) was added to the 
initial  culture, while priming for IFN-'y production involved the addition 
of anti-IL-4 (10/~g/ml) to the initial culture. 
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yield was <105 at 4 d, whereas in the presence of APC and 
peptide,  >107 cells were obtained. Among cells obtained 
after priming with peptide and APC, >92% were Mel-14  l~ 
and >99%  CD44  hi, indicating that the great majority of 
cells had been activated  as a result of the priming process 
(data not shown). This was true whether II:4, anti-I1:4, or 
neither had been added to the priming culture. 
The primed cells were washed and restimulated in 96-well 
plates at 105/0.2 ml with fresh DC (2  x  104/well) and pep- 
tide (1/xM). Supernatants were collected 36 h later and con- 
centrations of Ib4 and IFN-'), were measured (Fig. 2). The 
amount of I1:4 and IFN-',/produced in the secondary culture 
was multiplied by the yield of cells from primary culture to 
determine lymphokine  production per priming culture. Large 
amounts of I1:4 were produced by cells that had been primed 
in  the  presence  of I1:4;  no  other  population produced 
significant amounts of I1:4. By contrast, IFN-3~ was produced 
in substantial amounts by cell populations that had been 
primed without the addition of I1:4 or to which anti-I1:4 
had been added during priming; cells primed in the presence 
of I1:4 produced <100 U  IFN-3,/culture upon rechallenge 
(Fig.  2). 
Similar results were obtained when primed T  cells were 
restimulated with activated B cells and peptide, or with im- 
mobilized anti-CD3, indicating that the pattern oflymphokine 
production was determined by the priming conditions rather 
than by the restimulation conditions. Furthermore, the pat- 
tern of production of Ib2 in secondary cultures was similar 
to that of IFN-3,.  Cells primed with I1:4 produced little or 
no I1:2 upon secondary challenge,  whereas cells primed in 
the presence of anti-I1:4 produced substantial amounts of I1:2 
(data not shown). We also tested the priming of transgenic 
T  cells by intact cytochrome C, which gave results essen- 
tially the same as those obtained with peptide. 
11.,10 Does Not Inhibit Priming  for IFN-7 Production.  Ibl0 
has been demonstrated to diminish I1:2 and IFN-y produc- 
tion by T cell dones of the T,1 type, and is believed to exert 
its effects by acting on macrophages and possibly other APC 
(29). To determine whether II.-10 would inhibit priming of 
transgenic T cells for IFN-3, production and whether the effect 
of exogenous I1:4 inhibiting such priming might require en- 
dogenous production of I1:10, priming was carried out with 
concentrations of I1:4 ranging from 0 to 1,000 U/ml in the 
presence of either I1:10 or anti-I1:10  antibody (Fig.  3).  In 
the absence of II.-4, IL-10  did not significantly diminish  priming 
for IFN-'I' production, nor did it  cause priming for II.-4 
production.  Anti-I1:10 caused  a  modest enhancement in 
priming for IFN-'y production in the experiment illustrated 
in Fig. 4, but this effect was not observed in other experi- 
ments, suggesting that endogenously  produced I1:10 was not 
suppressing priming for IFN-3' production. At the optimal 
concentration of Ib4 (1,000 U/ml), priming for I1:4 was not 
affected by the presence of I1:10 or anti-IL-lO. No priming 
for IFN-3" was observed under these conditions even in the 
presence of anti-I1:10,  indicating that the effect of I1:4 in 
preventing priming for IFN-'y production is independent of 
I1:10. 
At  an  intermediate concentration of I1:4  (100 U/m1), pRIMARY (4 DAYS~ 
T CELLS, DC, 
88-104, IL-2 PLUS 
SECONDARY CULTURE (36 HRS,: T CELLS. DC. 81-104 
0  I  300  U/CULTURE 
IL-4  <100 U/CULTURE 
11Bll  1 1380U/CULTURE 
40000  80000  120000  16(X)00  0  2000  4000  6000  8000 10000 
IL-4 (U/Culture)  IFI~ (U/Culture) 
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Figure 2.  II~ is required for priming 
for 11"4  production  and inhibits priming 
for IFN-3' production. Naive CD4 + 
transgenic T cells (106) were primed by 
stimulation for 4 d with dendritic cells 
(2 x  104), peptide (10 tzM), and II.-2 
(10 U/ml), with or without I1"4 (1,000 
U/ml) or anti-I1"4 (10 #g/ml). Cells 
were washed and recuhured at 10s/200 
#I with dendritic cells (2  x  104) and 
peptide (1 #M) for 36 h. Supematants 
were harvested and tested for produc- 
tion of I1-4 and IFN-% Results are 
reported as lymphokine  production per 
priming culture (cell yield/10  s multi- 
plied by lymphokine production per 
lO  s cells). 
priming for I1-4 production was diminished and inhibition 
of priming for IFNw production was only partial.  Once again, 
I1-10 did not significantly enhance the inhibition of priming 
for IFN-3, production, nor did anti-IblO relieve the inhibition. 
Effect of lFN-'f on Priming Transgenic T Cells.  IFN-'y has 
been reported to inhibit the appearance ofT cell clones capable 
of producing  Ib4,  suggesting that it might  have an effect 
on the priming process (30). To examine this, transgenic T 
cells were primed in the presence ofofO, 100, or 1,000 U/ml 
oflb4 together with 0, 100, 500, and 2,500 U/ml of IFN-3, 
(Fig. 4). IFN-~/did not diminish priming for I1-4 produc- 
tion when an optimal concentration  of I1-4 (1,000 U/ml) 
was used, nor did anti-IFN-3, enhance priming for 11-4 produc- 
tion  in  the absence of Ib4.  However, when  a suboptimal 
priming concentration of II-4 (100 U/ml) was used, IFN-'y 
caused a substantial reduction in priming at all doses from 
100 to 2,500 U/ml, indicating that under certain conditions 
IFN-3' as well as I1-4 can regulate priming for ID4 production. 
We also wished to determine whether IFN-3, played a role 
in the priming for IFN-3' production. In the absence of IL-4, 
priming for IFN-~, production was not significantly enhanced 
by the addition of IFN-% nor did anti-IFN-3~  inhibit  such 
priming.  Furthermore,  IFN-'), did not overcome the inhibi- 
tory effects of I1.,4 in preventing priming for IFN-'y produc- 
tion. These results indicate that although IFN-3' plays an in- 
hibitory role in priming for Ib4 production when suboptimal 
concentrations of Ib4 are used, it does not have any striking 
effect on priming  for IFN-3, production. 
The Effect o.t"11-,4 in Determining Lymphokine-producing Ca- 
pacity Is Independent of APC Type.  To determine whether 
the  regulatory  role  of I1-4  in  determining  lymphokine- 
producing phenotype only held when certain types of APC 
were used for priming, we used DC, B ceils activated by cul- 
ture with LPS, and a fibroblast line that had been transfected 
with the I-E  k gene as APC in primary cultures (Fig.  5).  In 
each case, the presence of IL-4 during the primary response 
prepared the cells to produce IL-4 upon rechallenge with DC 
and peptide. In these experiments, cdls cultured with anti- 
Ib4 during the primary response produced IFN-3' but little 
Ib4 upon rechallenge.  In the experiment illustrated in Fig. 
5,  the ratio  of APC to T  cells was 1:50  for DC,  1:50  for 
activated B cells,  and 1:5 for fibroblasts, so that the superi- 
ority of DC over B cells  and of B cells over fibroblasts in 
degree of priming suggests that the type of APC affects the 
magnitude of priming rather than the pattern of lymphokines 
that are produced. In other experiments, a variety of densi- 
ties of APC have been utilized with generally similar results. 
Moreover,  B  cells  activated  with  anti-IgM  plus  Ib4,  T 
cell-depleted spleen cell populations, and nonadherent spleen 
cell populations used as APC gave similar results. These ex- 
T + DC + 88-104 + IL-2+: 
IL-4  IL-IO or alL-lO 
NONE 
0  IL-IO 
alL-10 
NONE 
100 (U/ML)  IL-10 
alL-10 
NONE 
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Figure  3.  Ibl0  does not  inhibit 
priming for IFN-3, production. CD4 § 
transgenic T cells (5 x  10  s) were cul- 
tured with dendritic cells (2.5 x 104), 
88-104 (0.1 #M), and I1-2 (10 U/ml) 
in the presence of 0-1,000 U/ml II:4 
and I1"10 (100 U/ml) or anti-ILl0 (10 
#g/ml). Supematants were assessed  for 
lymphokine production after restimu- 
lation, and results are reported as de- 
scribed in the legend to Fig. 2. 
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Figure4.  Relative effects ofll_-4andlFN-? 
on priming for lymphokine production. CD4  * 
T cells from transgenic mice were cultured as 
described in the legend to Fig. 4 in the pres- 
ence of 0-1,000 U/ml I1.4 and 0-2,500 U/ml 
IFN-% IL4 and ]FN-'), were measured in su- 
pernatants obtained after restimulation, and 
results are reported as described in the legend 
to Fig. 2.  Anti-IFN-7 (10/~g/ml) was also 
added to cells primed without IL-4 or IFN-% 
periments indicate that the presence or absence of Ib4 during 
the priming process determines the pattern of subsequent lym- 
phokine production, at least for the range of APC tested. 
Discussion 
There is now considerable evidence that few resting T  cells 
from naive donors produce IL-4 in response to initial stimu- 
lation, and that production of IFN-'), is also meager in such 
cell populations (5, 27, 31-34).  Rather, the production of 
these lymphokines depends upon a priming event. Previous 
studies with polyclonal activators demonstrated a critical role 
for IL-4 itself in determining the capacity of primed cells to 
produce Ib4 (5-7). The current studies make use of a model 
in which antigen specific T cells are primed by recognition 
of their cognate ligands on APC and thus allows a more phys- 
iologic approach to the determination of lymphokine-pro- 
ducing phenotype than is possible with polyclonal stimuli. 
There are several  possible mechanisms acting independently 
or together that may commit a naive T  cell population to 
produce particular lymphokines upon subsequent stimula- 
tion: (a) Lymphokines themselves may regulate the ability 
of naive T cells to become committed to production of var- 
ious lymphokines, as already demonstrated  by in vitro priming 
with polyclonal stimuli (5-7, 35). (b) Different types of APC 
may express distinct "costimulatory" molecules or express 
different amounts of class II MHC molecules that may affect 
the priming for distinct lymphokines. (c) The degree of stim- 
ulation through the TCR may cause the cell to differentiate 
down one or another pathway (36, 37). (d) It is possible that 
there is a direct link between the specificity of the TCR and 
the type of lymphokine that the cell may be primed to pro- 
duce. This could be achieved through thymic selection.  (e) 
Factors contributed by the antigen (or by the "agent" bearing 
the antigen) may have a critical deterministic role, presum- 
ably by acting on one or another of the cells that participate 
in the interaction. Such action may be indirect in that it recruits 
one of the other mechanisms discussed above. 
Several of these possibilities can be directly addressed using 
an in vitro priming system in which the T cells are derived 
from TCR transgenic mice. Using this model, we show that 
the  bulk  of dense  CD4 +  T  cells  from naive  transgenic 
donors behave as if they are resting cells. Most particularly, 
upon immediate challenge with peptide and various  types 
of APC, they produce small amounts of IL-4 or of IFN-% 
but, as we describe in some detail, appropriate priming causes 
the appearance of a vastly greater capacity  to produce one 
or another of these lymphokines. 
The most striking result is the dominant effect of IL-4 in 
determining the pattern of lymphokines produced upon sub- 
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Figure  5.  Lymphokine  and  APC 
control of priming for IL-4 and IFN? 
production.  CD4 + T cells from trans- 
genic donors were primed for 4 d under 
the same conditions as those described 
in the legend to Fig. 3, ew.cept that ac- 
tivity of dendritic  cells (2  x  104) as 
APC was compared with that of LPS- 
activated B  cells (2  x  104) or I-E  k- 
transf~cted L929 cells (fibroblasts)  (2 x 
10s). 36 h later snpernatants were har- 
vested and assessed for production of 
IL-4 and IFN-',/.  Results are reported 
as described in the legend to Fig. 2. sequent in vitro stimulation. When I1-4 is present during 
priming at a concentration of 1,000 U/ml, restimulation of 
these cells results in production of large amounts of I1-4 and 
of little or no IFN-3, or I1-2. The concentration of I1.4 used 
(1,000  U/ml  =  ~0.4  x  10 -10 M)  would  appear  to  be 
potentially within a physiologic range, since the I1-4 receptor 
binds II.-4 with an equilibrium constant of-10 l~ M-1 (38). 
Indeed, even lower concentrations of I1.4 (100 U/ml; ~0.04 
x  10-1~ MI  were  capable  of inducing priming  for  I1.4 
production, although they only partially inhibited the devel- 
opment of IFN-3~-producing capacity. 
Ibl0 has been reported to be an inhibitor of the produc- 
tion of I1-2 and IFN-3~ (39), raising the possibility that I1.,10 
might mediate the effect of I1.4 in inhibiting priming for 
IFN-3~ and I1.2 production. This possibility was ruled out 
by demonstrating that addition of II.-10 in the place of I1-4 
in the priming cultures did not lead to inhibition of IFN-3,- 
producing activity and that anti-I1-10 antibody did not block 
the effect of I1-4 in inhibiting priming for IFN-3r (Fig. 3). 
These results thus point to the direct action of Ib4  as an 
inhibitor of priming for IFN-',/production. 
In contrast to a requirement for II.-4 to allow subsequent 
II.,4 production, we failed to identify a lymphokine neces- 
sary for subsequent IFN-3, production. The addition of IFN-'y 
neither enhanced priming for IFN-3,-producing capacity, nor 
did anti-IFN-3' diminish this priming. In other studies, we 
failed to observe an effect of exogenous TGF-~/on priming 
for IFN-'y production, although we have not fully excluded 
a role for endogenously produced TGF-B (R.  A. Seder, et 
al., unpublished observations). Nonetheless, these initial results 
suggest the possibility that the acquisition of the capacity 
to produce IFN-'y as a result of priming may represent the 
"default" pathway of differentiation. The addition of I1-4 ap- 
pears to block this differentiation and to commit the cells 
to develop into II:4 producers. 
Our studies on the importance of I1-4 for the acquisition 
of the capacity to subsequently produce I1-4 are consistent 
with in vivo studies by Sadick et al. (8) and more recently 
Chatelain et al. (9), in which the injection of anti-I1-4 mAbs 
at the time of L. major infection allows susceptible mice to 
develop a protective response marked by IFN-3' production. 
Furthermore, injections of I1-4 were reported to cause mice 
that are normally resistant to L. major to become susceptible 
and to develop T  cells that produce I1-4 in response to an- 
tigen stimulation (9). It has also been shown that injection 
of anti-I1-4 at the time of immunization with hemoeyanin 
results  in  a reduction in the  frequency of I1-4-producing 
antigen-specific T  cells  and concurrently  increases  IFN-3' 
production (S. Z. Ben-Sasson et al., manuscript submitted 
for publication). These results provide very strong evidence 
of the physiological role of I1-4 in determining the pattern 
of lymphokine production. 
If I1-4  is an important physiologic agent in controlling 
priming for I1-4 and IFN-3' production, it is logical to ask 
what is its source in vivo. Indeed, primary cultures do pro- 
duce some II.-4 by 36 h of culture, as shown in Fig. 1, and 
capacity is increased by day 3 of initial culture. Although the 
amounts are insufficient for optimal priming for I1.4 produc- 
tion in vitro, it is possible that conditions in vivo may be 
such that the concentration achieved locally is adequate to 
initiate the positive feedback loop required for substantial I1.4 
production in subsequent responses. Among T cells, two major 
sources for such initial II.,4 production can be considered. 
T  cells that had been previously primed, possibly by cross- 
reactive antigens, could produce 11.4 upon antigenic chal- 
lenge.  Additionally,  Bendelac et  al.  (40)  have shown that 
CD4 +, CD44b~is  ht thymocytes are highly enriched in cells 
that produce I1.4 in response to immobilized anti-CD3, and 
that they retain this capacity to produce I1.4 for several days 
after emigrating to the periphery. These cells could respond 
to antigenic challenge with a burst of I1.4 production and 
thus provide the stimulus required for the longer lived T cells 
to develop into II_,4 producers. 
In addition, we have recently shown that FceRI + cells in 
spleen and bone marrow are highly enriched in cells of the 
basophil and/or mast cell lineage that are potent producers 
of I1.4 when stimulated by crosslinkage of FceRI or Fc3,RIII 
(41-43). It is possible that under conditions in which these 
cells are activated or increased in number, for example in hel- 
minthic infections, they provide a source of sufficient I1.4 
to amplify I1.4 production by T  cells. 
There has been extensive work using different types of APC 
to stimulate proliferation and lymphokine production from 
established CD4 + T cell clones. Gajewski et al. (44) showed 
that  B  lymphocytes  are  effective in  stimulating  T.2-type 
clones to proliferate, while splenic-adherent cells were effec- 
tive APC for clones of the T.l-type (44). Chang et al. (45) 
reported  that  B  cells  used  as  APC  cause  T.2  clones  to 
proliferate  suboptimally  unless  II.,1  was  added,  whereas 
proliferative responses to macrophages as APC did not re- 
quire exogenous I1.1. However, lymphokine production was 
similar using either cell type as APC and did not require I1-1 
(44). Our results indicate that among the APC we have tested 
(DC,  activated  B  cells,  I-Ek-transfected  fibroblasts,  and 
T-depleted spleen [data not shown]) all stimulated qualita- 
tively similar lymphokine responses in that I1-4 was required 
for priming for I1.4 production and suppressed priming for 
IFN-~" production, while priming for IFN-3, production oc- 
curred without the need to add an exogenous cytokine. How- 
ever,  in quantitative terms, DC were superior to activated 
B cells, which were superior to I-Ek-transfected fibroblasts. 
As discussed above, there is evidence that I1-1 is a neces- 
sary costimulator for proliferation of some T.2 clones,  al- 
though it is not required for lymphokine production. Koide 
and Steinman (46) showed that dendritic cells produce virtu- 
ally no I1-1 and questioned the need for I1-1 for lymphocyte 
activation. To address the question of whether I1-1 is required 
either for priming T  cells to produce I1.4 or for expansion 
of cells that become I1-4 producers, we performed experi- 
ments in which exogenous I1-1 or anti-I1-1 receptor anti- 
body were added to the priming cultures. Adding exogenous 
II_,1 in the absence of I1.4 did not prime cells to become I1-4 
producers, and adding an antibody to the type 1 II.-1 receptor 
in the presence of I1-4 did not inhibit priming for I1-4 produc- 
1096  lnterleukin 4 Regulates Priming for Lymphokine  Production tion (data not shown). Moreover, it has been shown that ad- 
dition of the II.-1 receptor antagonist to naive T cells in the 
presence  of a polyclonal stimulator and I1,4 does not effect 
the development of IL-4-producing cells (A. K. Abbas,  per- 
sonal communication). Thus, I1-1 does not appear to play 
a major role in the generation of lymphokine-producing cells 
from naive T  cells. 
Our results also show that cells producing either II,-4 or 
IFN-3' can have identical T  cell receptors.  Several TCR oz 
and ~ chains of T cell clones specific for antigens of L. major 
have been sequenced and instances have been observed in which 
identical sequences  for both chains occurred in clones that 
produced II.-4 or IFN-7 (S. L. Reiner, personal communica- 
tion), further arguing against a strong effect of receptor struc- 
ture on lymphokine producing capacity. 
From these studies we conclude that IL-4 is a critical regu- 
lator of the commitment of CD4 + T  cells to the produc- 
tion of I1:4 and to the inhibition of their production of IFN-3' 
and II,-2. This conclusion naturally leads to the question of 
what regulates the production of IL-4 involved in this initial 
decision process  and how different forms of immunization 
establish different patterns of lymphokine-producing T cells. 
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